G1 Therapeutics Q2 EPS $0.14 May Not Be Comparable To $(0.17) Estimate, Sales $42.39M Beat $28.34M Estimate
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics (NASDAQ:GTHX) reported Q2 earnings of $0.14 per share, beating the analyst consensus estimate of $(0.17) by 182.35%. This is a 115.22% increase over losses of $(0.92) per share from the same period last year. The company also reported quarterly sales of $42.39 million, beating the analyst consensus estimate of $28.34 million by 49.58%. This is a 300.95% increase over sales of $10.57 million the same period last year.
August 04, 2023 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
G1 Therapeutics reported strong Q2 earnings and sales, significantly beating estimates. This could lead to a positive short-term impact on the stock.
G1 Therapeutics reported a significant beat on both earnings and sales estimates for Q2. This strong performance, which includes a 115.22% increase in earnings and a 300.95% increase in sales YoY, is likely to be viewed positively by investors and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100